• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作为肝癌的诊断和预后生物标志物。

HN1 as a diagnostic and prognostic biomarker for liver cancer.

机构信息

Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China.

Department of Gastrointestinal and Colorectal Surgery, China-Japan Union Hospital, Jilin University, Changchun, Jilin 130033, P.R. China.

出版信息

Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20200316.

DOI:10.1042/BSR20200316
PMID:32700728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7396428/
Abstract

BACKGROUND

The present study aimed to examine the diagnostic and prognostic value of HN1 in terms of overall survival (OS) and recurrence-free survival (RFS) in liver cancer and its potential regulatory signaling pathway.

METHODS

We obtained clinical data and HN1 RNA-seq expression data of liver cancer patients from The Cancer Genome Atlas database, and analyzed the differences and clinical association of HN1 expression in different clinical features. We uesd receiver-operating characteristic curve to evaluate the diagnosis capability of HN1. We analyzed and evaluated the prognostic significance of HN1 by Kaplan-Meier curves and Cox analysis. Gene Set Enrichment Analysis (GSEA) was used to identify signaling pathways related to HN1 expression.

RESULTS

HN1 mRNA was up-regulated in liver cancer, and was associated with age, histologic grade, stage, T classification, M classification, and vital status. HN1 mRNA had ideal specificity and sensitivity for the diagnosis (AUC = 0.855). Besides, the analysis of Kaplan-Meier curves and Cox model showed that HN1 mRNA was strongly associated with the overall survival and could be well-predicted liver cancer prognosis, as an independent prognostic variable. GSEA analysis identified three signaling pathways that were enriched in the presence of high HN1 expression.

CONCLUSION

HN1 serves as a biomarker of diagnosis and prognosis in liver cancer.

摘要

背景

本研究旨在探讨 HN1 在肝癌总体生存率（OS）和无复发生存率（RFS）方面的诊断和预后价值及其潜在的调控信号通路。

方法

我们从癌症基因组图谱数据库中获得了肝癌患者的临床数据和 HN1 RNA-seq 表达数据，并分析了 HN1 表达在不同临床特征中的差异和临床关联。我们使用受试者工作特征曲线来评估 HN1 的诊断能力。我们通过 Kaplan-Meier 曲线和 Cox 分析来分析和评估 HN1 的预后意义。基因集富集分析（GSEA）用于鉴定与 HN1 表达相关的信号通路。

结果

HN1 mRNA 在肝癌中上调，并与年龄、组织学分级、分期、T 分类、M 分类和生存状态相关。HN1 mRNA 对诊断具有理想的特异性和敏感性（AUC = 0.855）。此外，Kaplan-Meier 曲线和 Cox 模型分析表明，HN1 mRNA 与总生存率密切相关，可以作为独立的预后变量很好地预测肝癌预后。GSEA 分析鉴定出了在高 HN1 表达时富集的三个信号通路。

结论

HN1 可作为肝癌诊断和预后的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/da5da4d816cf/bsr-40-bsr20200316-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/4386a4469a13/bsr-40-bsr20200316-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/76ea0c6564fd/bsr-40-bsr20200316-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/93c512b873a6/bsr-40-bsr20200316-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/0dab2feb5dd9/bsr-40-bsr20200316-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/0a1ab790d363/bsr-40-bsr20200316-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/f850a5243080/bsr-40-bsr20200316-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/da5da4d816cf/bsr-40-bsr20200316-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/4386a4469a13/bsr-40-bsr20200316-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/76ea0c6564fd/bsr-40-bsr20200316-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/93c512b873a6/bsr-40-bsr20200316-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/0dab2feb5dd9/bsr-40-bsr20200316-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/0a1ab790d363/bsr-40-bsr20200316-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/f850a5243080/bsr-40-bsr20200316-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c05/7396428/da5da4d816cf/bsr-40-bsr20200316-g7.jpg

相似文献

1
HN1 as a diagnostic and prognostic biomarker for liver cancer.作为肝癌的诊断和预后生物标志物。
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20200316.
2
Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.肝癌中 lncRNA LUCAT1 表达的临床价值及其潜在途径。
J Gastrointestin Liver Dis. 2019 Dec 9;28(4):439-447. doi: 10.15403/jgld-356.
3
Increased expression of hematological and neurological expressed 1 (HN1) is associated with a poor prognosis of hepatocellular carcinoma and its knockdown inhibits cell growth and migration partly by down-regulation of c-Met.血液和神经表达 1（HN1）的表达增加与肝细胞癌的预后不良有关，其敲低通过下调 c-Met 部分抑制细胞生长和迁移。
Kaohsiung J Med Sci. 2020 Mar;36(3):196-205. doi: 10.1002/kjm2.12156. Epub 2019 Nov 20.
4
Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients.鉴定一个与自噬相关的基因特征，可以改善肝癌患者的预后。
BMC Cancer. 2020 Aug 17;20(1):771. doi: 10.1186/s12885-020-07277-3.
5
Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.基于 TCGA 数据的肝癌肿瘤突变负荷和免疫浸润的预后分析。
Aging (Albany NY). 2021 Apr 4;13(8):11257-11280. doi: 10.18632/aging.202811.
6
Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.长链非编码 RNA 标志物预测肝细胞癌无复发生存率。
World J Gastroenterol. 2019 Jan 14;25(2):220-232. doi: 10.3748/wjg.v25.i2.220.
7
Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer.SPATS2在肝癌中的表达及其预后潜力的综合评估。
Medicine (Baltimore). 2020 Feb;99(9):e19230. doi: 10.1097/MD.0000000000019230.
8
GPSM2 Serves as an Independent Prognostic Biomarker for Liver Cancer Survival.GPSM2 可作为肝癌生存的独立预后生物标志物。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820945817. doi: 10.1177/1533033820945817.
9
Revealing the clinical significance and prognostic value of small nucleolar RNA SNORD31 in hepatocellular carcinoma.揭示小核仁 RNA SNORD31 在肝细胞癌中的临床意义和预后价值。
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20201479.
10
Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.SOCS1 和 SOCS3 肿瘤抑制因子及致癌信号通路基因在肝细胞癌中的预后意义。
BMC Cancer. 2020 Aug 17;20(1):774. doi: 10.1186/s12885-020-07285-3.

引用本文的文献

1
Validation of Two Prognostic Gene Scores in Patients Undergoing Liver Resection for Hepatocellular Carcinoma.两种预后基因评分在接受肝细胞癌肝切除术患者中的验证
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102544. doi: 10.1016/j.jceh.2025.102544. Epub 2025 Mar 11.
2
HN1 Functions in Protein Synthesis Regulation via mTOR-RPS6 Axis and Maintains Nucleolar Integrity.HN1通过mTOR-RPS6轴在蛋白质合成调控中发挥作用并维持核仁完整性。
Cell Prolif. 2025 Jun;58(6):e13805. doi: 10.1111/cpr.13805. Epub 2025 Jan 13.
3
Construction and validation of senescence risk score signature as a novel biomarker in liver hepatocellular carcinoma: a bioinformatic analysis.

本文引用的文献

1
Investigation of the Clinical Significance and Prognostic Value of the lncRNA in Liver Cancer.探讨 lncRNA 在肝癌中的临床意义和预后价值。
Biomed Res Int. 2019 Oct 30;2019:4602371. doi: 10.1155/2019/4602371. eCollection 2019.
2
High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer.MAST2mRNA 表达水平升高及其在肝癌诊断和预后中的作用。
Sci Rep. 2019 Dec 27;9(1):19865. doi: 10.1038/s41598-019-56476-x.
3
Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.肝癌中 lncRNA LUCAT1 表达的临床价值及其潜在途径。
衰老风险评分特征作为肝细胞癌新型生物标志物的构建与验证：一项生物信息学分析
Transl Cancer Res. 2024 Sep 30;13(9):4786-4799. doi: 10.21037/tcr-23-2373. Epub 2024 Sep 12.
4
Circular RNAs in hepatocellular carcinoma: Recent advances.肝细胞癌中的环状RNA：最新进展
World J Gastrointest Oncol. 2022 Jun 15;14(6):1067-1085. doi: 10.4251/wjgo.v14.i6.1067.
5
A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.一组预测肝细胞癌预后的E2F靶基因特征
Front Genet. 2022 May 3;13:879299. doi: 10.3389/fgene.2022.879299. eCollection 2022.
J Gastrointestin Liver Dis. 2019 Dec 9;28(4):439-447. doi: 10.15403/jgld-356.
4
Expression as a Prognostic Biomarker for Liver Cancer Patients.作为肝癌患者的预后生物标志物的表达。
Dis Markers. 2019 Oct 17;2019:9037131. doi: 10.1155/2019/9037131. eCollection 2019.
5
Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance.肝癌中 La 核糖核蛋白结构域家族成员 4B（LARP4B）的表达及其临床和预后意义。
Dis Markers. 2019 Oct 22;2019:1569049. doi: 10.1155/2019/1569049. eCollection 2019.
6
High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer.高过氧化物酶样表达是乳腺癌中一种潜在的独立预后生物标志物。
Medicine (Baltimore). 2019 Nov;98(44):e17703. doi: 10.1097/MD.0000000000017703.
7
PGM5: a novel diagnostic and prognostic biomarker for liver cancer.PGM5：一种用于肝癌的新型诊断和预后生物标志物。
PeerJ. 2019 Jun 11;7:e7070. doi: 10.7717/peerj.7070. eCollection 2019.
8
serves as a diagnostic and prognostic biomarker for pancreatic cancer.作为胰腺癌的诊断和预后生物标志物。
Onco Targets Ther. 2019 May 27;12:4141-4152. doi: 10.2147/OTT.S201675. eCollection 2019.
9
High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma.高表达的miR-454-3p预示肝细胞癌预后不良。
Cancer Manag Res. 2019 Apr 8;11:2795-2802. doi: 10.2147/CMAR.S196655. eCollection 2019.
10
Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.FAM64A mRNA 表达异常是胰腺癌患者生存不良的独立预测因子。
PLoS One. 2019 Jan 29;14(1):e0211291. doi: 10.1371/journal.pone.0211291. eCollection 2019.